<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000954</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 163</org_study_id>
    <secondary_id>11138</secondary_id>
    <nct_id>NCT00000954</nct_id>
  </id_info>
  <brief_title>A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma</brief_title>
  <official_title>Phase I/II Study of Combination Chemotherapy (Adriamycin, Bleomycin, +/- Vincristine) and Dideoxyinosine (ddI) or Dideoxycytidine (ddC) in the Treatment of AIDS-Related Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novum</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the toxicity and response to treatment with cytotoxic chemotherapy using&#xD;
      doxorubicin (Adriamycin), bleomycin, and vincristine (DBV) for advanced AIDS-related Kaposi's&#xD;
      sarcoma in combination with either didanosine (ddI) or zalcitabine (dideoxycytidine; ddC).&#xD;
&#xD;
      AIDS patients with extensive Kaposi's sarcoma require treatment with effective cytotoxic&#xD;
      agents to reduce the tumor burden, and they also require treatment with other possibly&#xD;
      effective antiretroviral agents such as ddI or ddC to ameliorate (delay) the development of&#xD;
      opportunistic infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIDS patients with extensive Kaposi's sarcoma require treatment with effective cytotoxic&#xD;
      agents to reduce the tumor burden, and they also require treatment with other possibly&#xD;
      effective antiretroviral agents such as ddI or ddC to ameliorate (delay) the development of&#xD;
      opportunistic infections.&#xD;
&#xD;
      In Phase I, eligible patients with advanced Kaposi's sarcoma are randomly assigned to either&#xD;
      ddI or ddC in combination with DBV chemotherapy. On the average, patients receive 12-44 weeks&#xD;
      of combined chemotherapy and antiretroviral therapy. If vincristine is deleted from Phase I&#xD;
      because of excess neurotoxicity, it will not be administered as part of the combination&#xD;
      chemotherapy if that treatment is continued in the Phase II study. The Phase II trial&#xD;
      proceeds when at least six cycles (12 weeks) of DBV have been completed by six patients&#xD;
      enrolled in Phase I, and an overall evaluation of tolerance to each combination treatment&#xD;
      plan has been completed. Study medication is administered as in Phase I, with the possible&#xD;
      deletion of vincristine. All patients who complete DBV chemotherapy with complete or partial&#xD;
      response or stable disease will continue to receive the originally assigned investigational&#xD;
      antiretroviral drug (ddC or ddI) for an additional 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">September 1996</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>72</enrollment>
  <condition>Sarcoma, Kaposi</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zalcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Prophylaxis for Pneumocystis carinii pneumonia for all patients with CD4 cell counts &lt;&#xD;
             200 cells/mm3.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Chemoprophylaxis for candidiasis, MAC, and herpes simplex.&#xD;
&#xD;
          -  Up to 14-day courses of metronidazole.&#xD;
&#xD;
          -  Recombinant erythropoietin.&#xD;
&#xD;
          -  Granulocyte-macrophage colony stimulating factor (GM-CSF) or granulocyte colony&#xD;
             stimulating factor (G-CSF) for patients with ANC &lt; 1000 cells/mm3.&#xD;
&#xD;
          -  Isoniazid for treatment of tuberculosis, with permission of the protocol chair, when&#xD;
             given in conjunction with pyridoxine.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Kaposi's sarcoma.&#xD;
&#xD;
        For patients &lt; 18 years of age:&#xD;
&#xD;
          -  consent of parent or guardian.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Opportunistic infection requiring treatment with myelosuppressive antibiotics (unless&#xD;
             on G-CSF or GM-CSF).&#xD;
&#xD;
          -  Other active malignancies except basal cell carcinoma of the skin or in situ cervical&#xD;
             carcinoma.&#xD;
&#xD;
          -  Prior history or current clinical evidence of peripheral neuropathy (= or &gt; grade 1),&#xD;
             pancreatitis, intractable diarrhea, or active seizure disorder not controlled by&#xD;
             antiseizure medication.&#xD;
&#xD;
          -  Significant pulmonary insufficiency (exertional dyspnea with minimal exertion, except&#xD;
             that due to pulmonary Kaposi's sarcoma) or cardiac insufficiency (New York Heart&#xD;
             Association status &gt; 2).&#xD;
&#xD;
          -  Neuropsychiatric history or altered mental status that would prevent informed consent&#xD;
             or that would not permit compliance with this protocol.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Myelosuppressive antibiotics (unless on G-CSF or GM-CSF).&#xD;
&#xD;
          -  Investigational agents other than drugs available on treatment IND and used for FDA&#xD;
             sanctioned indications, or other antiviral, immunomodulating or antitumor drugs.&#xD;
&#xD;
          -  Drugs associated with peripheral neuropathy (other than ddI, ddC, or vincristine),&#xD;
             including hydralazine, disulfiram, nitrofurantoin, cisplatin, diethyldithiocarbamate,&#xD;
             gold, rifampin, chloramphenicol, clioquinol, ethambutol, ethionamide, glutethimide,&#xD;
             sodium cyanate, and thalidomide.&#xD;
&#xD;
        Patients with the following prior conditions or symptoms are excluded:&#xD;
&#xD;
          -  Neuropsychiatric history or altered mental status that would prevent informed consent&#xD;
             or that would not permit compliance with this protocol.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Systemic treatment with doxorubicin, bleomycin, or vincristine.&#xD;
&#xD;
          -  Antitumor (Kaposi's sarcoma) drugs within 7 days of study entry.&#xD;
&#xD;
          -  Any investigational drug (other than drugs available on treatment IND and used for FDA&#xD;
             sanctioned indications) within 14 days of study entry.&#xD;
&#xD;
          -  Neurotoxic drugs (other than ddI or ddC) within 30 days of study entry.&#xD;
&#xD;
          -  Intralesional injections to a Kaposi's sarcoma marker lesion within 30 days of study&#xD;
             entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Irradiation of a Kaposi's sarcoma marker lesion within 30 days of study entry.&#xD;
&#xD;
        Alcohol consumption is strongly discouraged.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsuyasu RT</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Gill PS</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>USC CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bmc Actg Crs</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Buffalo, Erie County Medical Ctr.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Ctr.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mitsuyasu R, et al. Combination chemotherapy, adriamycin, bleomycin, vincristine (ABV) with dideoxyinosine (ddI) or dideoxycytidine (ddC) in advanced AIDS-related Kaposi's sarcoma (ACTG 163). Proc Annu Meet Am Assoc Cancer Res. 1995;14:A822</citation>
  </reference>
  <reference>
    <citation>Mitsuyasu R, Gill P, Paredes J, Ambinder R, Ratner L, Feldstein M. Preliminary results of a phase I/II trial of combination chemotherapy (ABV) with ddI or ddC in AIDS-related Kaposi's sarcoma (ACTG 163). Int Conf AIDS. 1993 Jun 6-11;9(1):396 (abstract no PO-B12-1565)</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vincristine</keyword>
  <keyword>Sarcoma, Kaposi</keyword>
  <keyword>Zalcitabine</keyword>
  <keyword>Didanosine</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Drug Interactions</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Combined Modality Therapy</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Antineoplastic Agents, Combined</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Bleomycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Zalcitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

